Parisa Azerang

Dr. Parisa Azerang


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2022 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
HJHoda Jamshidi
Hoda Jamshidi
MNMohammad Reza Naimi-Jamal
Mohammad Reza Naimi-Jamal
MSMaliheh Safavi
Maliheh Safavi
KRKimia RayatSanati
Kimia RayatSanati
PAParisa Azerang
Parisa Azerang
ATAzar Tahghighi
Azar Tahghighi


11 December 2012 in DARU Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
PAParisa Azerang
Parisa Azerang
ARAli Hossein Rezayan
Ali Hossein Rezayan
SSSoroush Sardari
Soroush Sardari
FKFarzad Kobarfard
Farzad Kobarfard
MBMitra Bayat
Mitra Bayat
KTKimia Tabib
Kimia Tabib
Background: The emergence of multidrug-resistant strains of Mycobacterium tuberculosis (Mtb) has intensified efforts to discover novel drugs for tuberculosis (TB) treatment. Targeting the persistent state of Mtb, a condition in which Mtb is resistant to conventional drug therapies, is of particular interest. Methods: This study is focused on propargyl acetate derivatives. Eight molecules were designed based on propargyl alcohols and different acid anhydrides. Results: All the synthesized compounds and commercially available ones were evaluated for anti-tuberculosis activity. Conclusions: Inhibitors against Mtb have been identified and characterized for further development into potential novel anti-tubercular drugs.

3 July 2024 in Research on Chemical Intermediates
Verified
Journal Article
Closed access
PDF file
NHNasrin Saberi Harooni
Nasrin Saberi Harooni
FTFatemeh Dehghani Tafti
Fatemeh Dehghani Tafti
NMNazanin Moghaddam
Nazanin Moghaddam
HNHossein Naeimi
Hossein Naeimi
PAParisa Azerang
Parisa Azerang
ATAzar Tahghighi
Azar Tahghighi

1 April 2021 in Current Computer-Aided Drug Design
Verified
Journal Article
Closed access
PDF file
ADAsghar Davood
Asghar Davood
ARAneseh Rahimi
Aneseh Rahimi
MIMaryam Iman
Maryam Iman
PAParisa Azerang
Parisa Azerang
SSSoroush Sardari
Soroush Sardari
AMArash Mahboubi
Arash Mahboubi
Objective(s): Azole antifungal agents, which are widely used as antifungal antibiotics, inhibit cytochrome P450 sterol 14α-demethylase (CYP51). Nearly all azole antifungal agents are N-substituted azoles. In addition, an azolylphenalkyl pharmacophore is uniquely shared by all azole antifungals. Due to importance of nitrogen atom of azoles (N-3 of imidazole and N-4 of triazole) in coordination with heme in the binding site of the enzyme, here a group of N- un-substituted azoles in which both of nitrogen is un-substituted was reported. Materials and Methods: Designed compounds were synthesized by reaction of imidazole-4-carboxaldehyde with appropriate arylamines and subsequently reduced to desired amine derivatives. Antifungal activity against Candida albicans and Saccharomyces cervisiae were done using a broth micro-dilution assay. Docking studies were done using AutoDock. Results: Antimicrobial evaluation revealed that some of these compounds exhibited moderate antimicrobial activities against tested pathogenic fungi, wherein compound 3, 7 and 8 were potent. Docking studies propose that all of the prepared azoles interacted with 14α-DM, wherein azole-heme coordination play main role in drug-receptor interaction. Conclusion: Our results offer some useful references in order to molecular design performance or modification of this series of compounds as a lead compound to discover new and potent antimicrobial agents.

1 March 2024 in Iranian Biomedical Journal
Verified
Journal Article
Open access
PDF file
EBElmira Karimzadeh Barenji
Elmira Karimzadeh Barenji
SBShokufeh Beglari
Shokufeh Beglari
ATAzar Tahghighi
Azar Tahghighi
PAParisa Azerang
Parisa Azerang
MRMahdi Rohani
Mahdi Rohani
Background: Lactic acid bacteria produce various beneficial metabolites, including antimicrobial agents. Owing to the fast-rising antibiotic resistance among pathogenic microbes, scientists are exploring antimicrobials beyond antibiotics. In this study, we examined four Lactobacillus strains, namely L. plantarum 42, L. brevis 205, L. rhamnosus 239, and L. delbrueckii 263, isolated from ...